Skip to main content
Fig. 8 | Arthritis Research & Therapy

Fig. 8

From: Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Fig. 8

Effect of repeated administration of CR6086, methotrexate (MTX), and their combination in arthritic mice (collagen-induced arthritis [CIA] model). Mice immunised with bovine type II collagen as described in the Methods section of the main text were recruited upon arthritis onset and randomised into experimental groups. Animals were treated with test drugs for 16 days. CR6086 was administered orally once daily, whereas MTX was administered intraperitoneally every third day. Clinical score (a) and paw volume (b) are expressed as AUC values from randomisation to the end of treatment. Data represent the mean ± SEM of 12 mice/group. P values vs vehicle-treated mice are indicated over each bar and were calculated by one-way analysis of variance followed by Dunnett’s test for multiple comparisons. P values over connecting lines indicate t test comparisons between combination treatment with 3 mg/kg MTX and each single treatment

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us